Douglas Cerretti - Cellcyte Genetics Insider

CCYG -- USA Stock  

USD 0.0006  0.00  0.00%

President, Chief Science Officer and Director of Bus. Devel.
Dr. Douglas P. Cerretti, Ph.D., is President of CellCyte Genetics Corporationrationration. He is a biopharmaceutical research scientist with experience in drug development in inflammation and cancer. From 1984 to 2002, he served with Immunex, and, after Immunex acquisition in 2002, with Amgen in positions ranging from Staff Scientist through Scientific Director. Dr. Cerretti retired from Amgen in 2007. He is the author or coauthor of more than 100 scientific publications and has over 40 issued US Patents to his name
Age: 61  President Since 2010  Ph.D    
425-519-3755  http://www.cellcyte.com
Cerretti has worked with Company since October 2009, initially as Chief Science Officer and Director of Business Development, where he helped formulate scientific and business strategies. He has also worked as a senior scientific consultant through DPC BioPharma Consulting of Seattle, Washington since 2008, formulating a business plan and scientific strategies for a potential stem cell product. From 2002 through 2007, Dr. Cerretti served as Scientific Director and Senior Research Scientist, Department of Cancer Biology for Amgen Corporationrationrationration. From 1984 through 2002, he served as a Senior Research Scientist for Immunex Corporationrationrationration within their departments of Vascular and Molecular Biology.

Management Efficiency

The company has return on total asset (ROA) of (415.29) % which means that it has lost $415.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.9) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

CellCyte Genetics Corporation, a development stage biotechnology company, engages in the research and development of medical devices for cell expansion and maintenance in the United States. The company was founded in 2005 and is based in Bellevue, Washington. Cellcyte Genetics is traded on BATS Exchange in USA.Cellcyte Genetics [CCYG] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Cellcyte Genetics Management Team

John Fluke, Chairman
Randy Lieber, Director, CPA
Douglas Cerretti, President, Ph.D

Stock Performance Indicators

Current Sentiment - CCYG

Cellcyte Genetics Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Cellcyte Genetics. What is your opinion about investing in Cellcyte Genetics? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Cellcyte Genetics and U S Bancorp. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.